Another piece of the puzzle.
On April 15, 2013, Amarantus Bioscience Holdings, Inc. appointed Russell Miller as Director of Investor Relations. Mr. Miller previously served as Director of Investor Relations for US Data Works and for Force Protection, Inc.
Director of Investor Relations
Russell is the former Director of Investor Relations for Force Protection, Inc., a leading provider of MRAP vehicles to the US Military. During his tenure at the company, Force Protection’s market capitalization grew from less than $1 million to $2 billion. Force Protection was acquired by General Dynamics in November of 2011.
As a consultant, Russell has successfully structured and participated in private placements, mezzanine financing, joint ventures, mergers and acquisitions, reverse mergers and acquisitions for companies on the OTC, American Stock Exchange and NASDAQ.
Russell has assisted a multitude of companies with their strategic plans for growth, liquidity, and return on equity by facilitating relationships with investment bankers, government institutions.
Russell relies on his broad range of worldwide contacts throughout the investment banking community, which include a large number of accredited investors and institutions from around the world.
I don't think a "big pharma" drug company is going to enter into a partnership agreement with Mannkind prior to the next F.D.A. decision. The diminished lung capacity issue could results in a number of "REMS" requirements placed on Afrezza.
The liability issue could be a stumbling block. I think "thestreet" has similar expectations.
80% probability of E.U. approval.
The Vivus news regarding the REMS modification actually helps Arena.
Please don't sell them any on these minor bear raids.
As Bogart said, "You'll regret it. Maybe not today or tomorrow but soon and for the rest of your life."